Profile
Lead is a dense metal long associated with radiation shielding, but it also forms radioisotopes valuable in medicine. Lead-212 is a synthetic radioisotope produced for treatment, with a half-life of about 10.6 hours.
Lead-212 is itself a beta emitter, but its importance lies in acting as an in-vivo generator. Once delivered to a tumour it decays into short-lived daughters that release potent, short-range alpha particles, concentrating cell-killing energy where it is needed. Its practical half-life allows time for radiolabelling and delivery, and it pairs with lead-203 for imaging.
Lead-212 is linked to targeting molecules such as somatostatin analogues for neuroendocrine tumours and PSMA ligands for prostate cancer, with early clinical results reported for agents including lead-212 DOTAMTATE.
Lead-212 is obtained from generator systems that separate it from longer-lived parent isotopes, thorium-228 or radium-224. Its supply therefore depends on access to that scarce parent material within the thorium decay series.
StandardX is developing accelerator-driven production to secure and scale the parent supply behind reliable lead-212 generators.